Drug Trial Radar · NCT00471497
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Last checked: Nov 19, 2026Latest source record: Nov 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
846
Actual
Start
Jul 31, 2007
Primary completion
Sep 2, 2009
Study completion Aug 21, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 10, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, were compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP). An extension protocol was included in this study design to allow patients who did not show sufficient response to their assigned treatments the opportunity to receive imatinib 400 mg BID (option available until protocol amendment 7) or nilotinib 400 mg BID, using an abbreviated safety and efficacy assessment schedule.
Conditions
- Myelogenous Leukemia, Chronic
Interventions
nilotinibDrug
Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
imatinibDrug
Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With ImputationTime frame: Baseline, 12 months
- Percentage of Participants With MMR at 12 Months Between All 3 Arms by Sokal Risk Group With ImputationTime frame: 12 months
Locations
213 sites in 35 countries. Site status is shown where the registry gives one.
University of California at Los Angeles Dept. of Hematology Clinic
Los Angeles, California
Kaiser Permanente - California Southern Dept of Kaiser South 3
San Diego, California
Kaiser Permanente - California Northern Vallejo Med Center/Med Offices
Vallejo, California
Kaiser Permanente - California Northern Kaiser Med
Vallejo, California
Rocky Mountain Cancer Centers RMCC - Colorado Springs
Greenwood Village, Colorado
Florida Cancer Specialists Dept. FloridaCancerSpecialists
Fort Myers, Florida
Advanced Medical Specialties Research Dept.
Miami, Florida
Cancer Centers of Florida PA Cancer Centers of FL
Ocoee, Florida
Florida Retina Institute Flordia Cancer Affilates
Orlando, Florida
University of Chicago Section of Hematology/Oncology
Chicago, Illinois
Indiana Blood and Marrow Institute Dept. of Indiana Blood&Marrow
Beech Grove, Indiana
University of Iowa Hospitals and Clinics Dept.of U of Iowa Hosp&Clinics
Iowa City, Iowa
Kansas City Cancer Center KCCC Business Office
Overland Park, Kansas
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center
New Orleans, Louisiana
Michigan State University / Breslin Cancer Center Breslin Cancer Center
Lansing, Michigan
Missouri Cancer Associates Dept. of Boone Hospital Center
Columbia, Missouri
Hematology Oncology Consultants, Inc. Deptof Hem. Onc.Consunsultants
St Louis, Missouri
Hackensack University Medical Center Department of Research
Hackensack, New Jersey
Memorial Sloan Kettering Cancer Center Clinical Trials Office
New York, New York
University of North Carolina UNC Lineberger Cancer Center
Chapel Hill, North Carolina
Wake Forest University Health Sciences Dept. of Industry Research
Winston-Salem, North Carolina
University of Cincinnati / Barrett Cancer Center Dept.of Internal Med.
Cincinnati, Ohio
Cleveland Clinic Foundation CCF
Cleveland, Ohio
Northwest Cancer Specialists Compass Oncology -BKM
Portland, Oregon
Cancer Centers of the Carolinas CC of C -Eastside
Greenville, South Carolina
Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
Chattanooga, Tennessee
Tennessee Oncology Dept. of Centennial Medical
Nashville, Tennessee
Texas Cancer Center ( Medical City Dallas Hospital)
Dallas, Texas
Cancer Care Centers of South Texas HOAST CCC of So.TX- Medical Center
San Antonio, Texas
Tyler Cancer Center
Tyler, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
La Plata, Buenos Aires, Argentina
Novartis Investigative Site
Salzburg, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Charleroi, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Yvoir, Belgium
Showing 40 of 213 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.